Recently, Novartis notified doctors of a revision in the labeling of Gleevec. The Precautions Section of the Gleevec label will now include a statement that there have been reports of patients who have developed severe congestive heart failure and left ventricular dysfunction while using Gleevec. The new labeling came after Nature Medicine published an article which looked at 10 Gleevec patients who developed severe congestive heart failure and left ventricular dysfunction. The Nature Medicine article also reported on pre-clinical studies showed that Gleevec-treated mice developed left ventricular dysfunction. Gleevec is used to treat certain types of cancer.
Comments are closed.